$IPA News

Last published 5mo ago

5mo agoOCX IPAInterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of DirectorsPR NewswireInterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions,...
5mo agoARGX CGEM HYFT IDXX+2The Biology Came First.Business WireOver 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological
1y agoIPAImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT"Business WireAn Evolution in Name, Structure, and Strategy Reflecting the Company's AI-Driven Platform and Bio-Native Discovery Vision ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), ImmunoPrecise Antibodies
1y agoIPAImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New YorkBusiness WireImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September
1y agoIPAImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody GenerationBusiness WireManufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"),
1y agoIPAAVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.Business WireArlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of
1y agoIPAImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI InnovationBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based
1y agoIPAImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call TranscriptEarnings Call Transcripts
1y agoIPAImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDABusiness WireImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for
1y agoIPAImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the ClinicBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating
1y agoIPAImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory BoardBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to
1y agoIPAIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025Business WireThe Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation
1y agoIPAImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The
1y agoIPAImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of DirectorsBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber
1y agoIPAImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training DataBusiness WireNew benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. ImmunoPrecise Antibodies
1y agoIPAImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® TechnologyBusiness WireFollow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential ImmunoPrecise (NASDAQ:IPA), a leader in AI-driven biotherapeutics, provides a significant update
1y agoIPAAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation StudiesBusiness WireBreakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a leader in AI-powered drug
1y agoIPAImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine DiscoveryBusiness WireLENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics,
1y agoIPAImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement EffortsBusiness WireImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced it has engaged CORE IR, a strategic investor and public relations firm, to support the Company's ongoing investor
1y agoIPAImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech ConferenceBusiness WireTuesday, June 3rd at 11:00 a.m. EDT ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced that Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd., will be
1y agoIPAIPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedBusiness WireImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping
1y agoIPAImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing MethodsBusiness WireImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration's (FDA) recent decision to phase out animal testing
1y agoIPAImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025Business WireSecures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through
1y agoIPAImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.Business WirePrograms to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs ImmunoPrecise
1y agoIPAIPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025Business WireThe Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the
1y agoIPAIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025Business WireThe Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that it
1y agoIPAIPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in ImmunotherapyBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology
1y agoIPAImmunoPrecise Antibodies Announces Key Leadership ChangesBusiness WireImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its
1y agoIPAImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance PeriodBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced that its application to transfer its securities to the Nasdaq
1y agoIPAImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville DebentureBusiness WireIPA Successfully Executes Strategic Capital Initiatives, Strengthening Financial Position for Growth ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ:IPA), a leader in AI-driven antibody discovery and
1y agoIPAIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes TreatmentBusiness WireImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction
1y agoIPAImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationBusiness WireImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced
1y agoIPAIPA Announces Resignation of Chief Financial OfficerBusiness WireImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of
1y agoIPAImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share PurchasesBusiness WireIPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its
1y agoIPAIPA to Present at The Microcap Conference 2025Business WireIPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference
1y agoIPAImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoIPAImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025Business WireDelivers $6.1 Million Q2 Revenue and Announces Strategic Plan to Reshape Biotech and AI-Driven Drug Discovery IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research
1y agoIPAIPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor ConferenceBusiness WireIPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company's 13th Annual
1y agoIPAIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024Business WireThe Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced that
1y agoIPA$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesBusiness WireInnovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), a leader in
2y agoIPAImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationBusiness WireImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from
2y agoIPAImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI TechnologyBusiness WireRabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ:IPA), an AI-driven
2y agoIPAImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024Business WireImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA's AI
2y agoIPAImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein DesignBusiness WireUniversity of Washington's Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven
2y agoIPAImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody DevelopmentsBusiness WireRabbit B Cell Select® Drives Clinical Breakthroughs in Cancer Treatment ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an
2y agoIPAImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call TranscriptEarnings Call Transcripts
2y agoIPAImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025Business WireAchieves $5.3 Million First Quarter Revenue, Reaches Milestone Developing Antibodies End-to-End Using LENSai IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven
2y agoIPAIPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024Business WireThe Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an artificial intelligence-driven biotherapeutic research and technology company,
2y agoIPAImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New YorkBusiness WireImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), is pleased to announce that it will be attending H.C. Wainwright's 26th Annual Global Investment Conference (the "Global Investment
2y agoIPAImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid RequirementsBusiness WireImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutics company, announced today that the Company received written notification (the "Notification Letter") from the